Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ Drug Pricing Chief Renews Call for Fundamental Review of Off-Year Re-Pricing
June 10, 2022
- Takata Pharma President Hiroki Takada Becomes New JGA Chief
June 1, 2022
- FPMAJ Chief Vows to Go on Offensive in Pricing Debate, Flags Japan’s Decline in Global Market
May 30, 2022
- JMA President Hopeful Matsumoto Vows to Boost Collaboration with Doctors, Govt; Matsubara Files for Election
May 25, 2022
- JMA Chief Nakagawa Drops Bid for Re-Election, Matsumoto Is Likely Winner
May 24, 2022
- PhRMA Hails Launch of Indo-Pacific Economic Framework
May 24, 2022
- INES-Led Coalition Calls for Patient/Citizen Participation in Healthcare Policymaking
May 23, 2022
- Japan, US, European Pharma Groups Prod Price Maintenance of Patented Drugs in Joint Pitch towards Honebuto
May 17, 2022
- PhRMA Urges Japan to Exclude Patented Products from Off-Year Re-Pricing in 2023, Create Innovation Ecosystem
May 17, 2022
- JPMA Takes Issue with WTO IP Waiver Proposal for COVID Vaccines
May 13, 2022
- Lagevrio Given to 87,000 via Pharmacies, Paxlovid to 120 as of April 15
May 9, 2022
- FPMAJ Official Prods Rethink of Off-Year Price Revision as Ukraine War Pushes Up Costs
April 27, 2022
- JPMA Think Tank Analyzing Cause of Expanding Drug Lag, Over 70% of US/EU Approved Meds Not Available in Japan
April 27, 2022
- JGA Suspends Kyowa Pharma for 5 Years after GMP Violations
April 25, 2022
- Predictability of Drug Pricing Must Be Ensured: EFPIA Japan Director General
April 22, 2022
- Mediceo Dodged Charges and FTC Penalties, but Still Barred from JCHO Bids
April 12, 2022
- FPMAJ Looks into Impact of Shanghai COVID-19 Lockdown
April 11, 2022
- Asian Pharma Groups to Boost Drug Discovery Collab via RWD Use
April 7, 2022
- Drug Damage Watchdog Calls for Temporary Suspension of Lagevrio Use
April 6, 2022
- JPMA Chief Sees Free Pricing Proposal as Catalyst for Active Reform Debate
April 5, 2022
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…